Adam F Today on ZIOP . Big Positive for ZIOP, Palifosfamide Now Full Approval. posted.
The Street March 15, 2013 Stock Mailbag
Ziopharm Oncology (ZIOP_) update: Following "close dialogue" with the FDA, palifosfamide will now be considered for full approval as a treatment for sarcoma based on a progression-free survival benefit, a company spokesperson told me. Previously, PFS was only being considered as the basis for accelerated approval with overall survival required for full approval.
The change is positive news for Ziopharm